| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 27, 2016One of the world’s top specialty biotherapeutics companies, CSL Behring continues to introduce innovations to address unmet medical needs or enhance current treatments
27 Oct 2016 Marcum LLP and Philadelphia SmartCEO magazine have recognized CSL Behring with the 2016 Innovator Breakthrough Award for developing novel products that save lives and improve quality...
-
Oct 7, 2016Many Rare Disease Patients Would Not Have Treatments Available to Them without an Adequate Supply of Human Plasma, and patients call plasma donors "heroes" for their lifesaving contributions.
07 Oct 2016 More than 1,000 plasma donations may be needed to treat one adult patient with a rare disease for a year During International Plasma Awareness Week, plasma donors are recognized by...
-
Oct 3, 2016CSL Behring announced that the Australian Therapeutic Goods Administration (TGA) has approved IDELVION®[albutrepenonacog alfa] in patients with haemophilia B (congenital factor IX deficiency).
03 Oct 2016 IDELVION is a long-acting recombinant albumin fusion protein for children and adults with haemophilia B, and is the first CSL Behring recombinant factor product to receive TGA approval...
-
Sep 29, 2016Global biotherapeutics leader CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IDELVION® [Albutrepenonacog Alfa], its innovative, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the prevention of bleeding tendency in patients with factor IX deficiency.
29 Sep 2016 IDELVION® delivers high-level protection from bleeds by maintaining factor IX activity levels at an average of 20 percent in patients treated prophylactically every 7-days and an...
-
Sep 21, 2016CSL Behring is proud to be a platinum sponsor of the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID) this week in Barcelona
21 Sep 2016 Hizentra® - the only 20% concentration SCIG with a proven track record of safety and efficacy for over 6 years; trusted by more than 18,000 patients and providers worldwide Privigen®...